Key facts
- This page summarizes Daniel N. Swisher Jr.'s Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Mar 2023, 20:26.
Daniel N. Swisher Jr. - 03 Mar 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)
- Reporting relationship
- President and COO
- Issuer ticker
- JAZZ
- Reported as of
- 03 Mar 2023
- Net transaction value
- -$774,724
- SEC form
- 4
- Accepted by SEC
- 07 Mar 2023, 20:26:21 UTC
- Prior SEC filing
- 07 Dec 2022
- Next SEC filing
- 23 May 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/Adam Guttmann, as attorney in fact For: Daniel Newell Swisher
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel N. Swisher Jr. filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 07 Mar 2023.
Change
- Previous filing in this sequence was filed on 07 Dec 2022.
- Current net transaction value: -$774,724.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JAZZ
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +13,456
- Change %
- +29%
- Price
- $0.000000
- Shares after
- 60,440
- Date
- 03 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
JAZZ
transaction
Ordinary Shares
Tax liability
- Transaction value
- $774,724
- Shares
- -5,426
- Change %
- -9%
- Price
- $142.78
- Shares after
- 55,014
- Date
- 05 Mar 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
Footnote F2
Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.